Monitoring disease activity in MS using serum neurofilament light protein

Best Practice Nordic | Sept 2019 | ECTRIMS 2019 |

Determination of Neurofilament light in blood may improve the assessment of patients and should be considered as part of No Evidence of Disease Activity. In this MEDtalk Jan Lycke talks about that Neurofilament light (NFL) has the potential to become the first soluble biomarker to monitor disease activity and treatment response in clinical practice of MS.